Trial Condition(s):

Prostatic Neoplasms, Castration-Resistant

Navigant study- treatment patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer ) (Navigant)

Bayer Identifier:

18919

ClinicalTrials.gov Identifier:

NCT02899104

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.

Inclusion Criteria
- Patients were diagnosed with bone metastatic castration-resistant prostate cancer (mCRPC) per medical chart. 
 - Patients were at least 18 years of age as of the first diagnosis for mCRPC.
 - Patients must have received at least one intravenous injection of Radium-223 (Xofigo). 
 - First injection of Radium-223 must have started between periods 
        1-January-2014 to 30-June-2014 or 15-November-2014 to present. 
 - Patients must have a minimum of 12 months documented follow-up records following last Radium-223 treatment or death within 12 months of last dose.
Exclusion Criteria
- Patients who received Radium-223 as part in an interventional clinical trial
 - Actively treated, or expect to be treated, in 6 months before last follow-up, for any other malignancy with the exception of non-metastatic skin cancer or low-grade superficial bladder cancer.

Trial Summary

Enrollment Goal
200
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Whippany

Whippany, United States, 07981

Status
Completed
 

Trial Design